buy mestinon-Pyridostigmine is a medication that we can use to treat myasthenia gravis. It is also help together with atropine to end the effects of neuromuscular blocking medication of the non-depolarizing type.
Mestinon (pyridostigmine) is available in the following forms: Syrup containing 60 mg pyridostigmine bromide per teaspoonful in a vehicle containing 5% alcohol, glycerin, lactic acid, sodium benzoate, sorbitol, sucrose, FD&C Red No. 40, FD&C Blue No. 1, flavors and water. Tablets containing 60 mg pyridostigmine bromide; each tablet also contains lactose, silicon dioxide and stearic acid. Timespan Tablets containing 180 mg pyridostigmine bromide; each tablet also contains carnauba wax, corn-derived proteins, magnesium stearate, silica gel and tribasic calcium phosphate.
Mestinon (pyridostigmine) is useful in the treatment of myasthenia gravis.
DOSAGE AND ADMINISTRATION
Mestinon (pyridostigmine) is available in three dosage forms:
Syrup – raspberry-flavored, containing 60 mg pyridostigmine bromide per teaspoonful (5 mL). This form permits accurate dosage adjustment for children and “brittle” myasthenic patients who require fractions of 60 mg doses. It is more easily swallowed, especially in the morning, by patients with bulbar involvement.
Conventional Tablets – each containing 60 mg pyridostigmine bromide.
Timespan Tablets – each containing 180 mg pyridostigmine bromide. This form provides uniformly slow release, hence prolonged duration of drug action; it facilitates control of myasthenic symptoms with fewer individual doses daily. The immediate effect of a 180 mg Timespan Tablet is about equal to that of a 60 mg Conventional Tablet; however, its duration of effectiveness, although varying in individual patients, averages 2½ times that of a 60 mg dose.
Dosage: The size and frequency of the dosage must adjust to the needs of the individual patient.
Syrup and Conventional Tablets – The average dose is ten 60 mg tablets or ten 5 mL teaspoonfuls daily, we can space to provide maximum relief when maximum strength is needed. In severe cases you may require as many as 25 tablets or teaspoonfuls a day, while in mild cases one to six tablets or teaspoonfuls a day may suffice.
Timespan Tablets – One to three 180 mg tablets, once or twice daily, will usually be sufficient to control symptoms; however, the needs of certain individuals may vary markedly from this average. The interval between doses should be at least 6 hours. For optimum control, it may be necessary to use the more rapidly acting regular tablets or syrup in conjunction with Timespan therapy.
Syrup, 60 mg pyridostigmine bromide per teaspoonful (5 mL) and 5% alcohol – bottles of 16 fluid ounces (1 pint) (NDC 0187-3012-20).
Tablets, are available as white, flat-faced tablets containing 60 mg pyridostigmine bromide in bottles of 100 (NDC 0187-3010-30) and 500 (NDC 0187-3010-40).
Timespan Tablets are available as light straw-colored, capsule-shaped tablets containing 180 mg pyridostigmine bromide in bottles of 30 (NDC 0187-3013-30).
Note: Because of the hygroscopic nature of the Timespan Tablets, mottling may occur. This does not affect their efficacy.
Store Mestinon (pyridostigmine) Tablets, Timespan Tablets, and Syrup at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F). Keep Mestinon (pyridostigmine) Tablets and Timespan Tablets in a dry place with the silica gel enclosed.
The side effects of Mestinon (pyridostigmine) are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness. Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.
Pyridostigmine is mainly excreted unchanged by the kidney.6,7,8 Therefore, we may require lower doses in patients with renal disease. And treatment should be based on titration of drug dosage to effect.
Mestinon (pyridostigmine) is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Should observe in the use of atropine for counteracting side effects, as discussed below.